Review article: The management of side-effects during therapy for hepatitis C

Alimentary Pharmacology and Therapeutics

Volumn 20, Issue 9, 2004, Pages 917-929

  Aspinall, R J ^a   Pockros, P J ^a  

^a SCRIPPS CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMPHETAMINE; ANTIBIOTIC AGENT; ANTIDEPRESSANT AGENT; ANTIVIRUS AGENT; CITALOPRAM; FLUOXETINE; GRANULOCYTE COLONY STIMULATING FACTOR; IMIPRAMINE; LEVOVIRIN; LIOTHYRONINE; LITHIUM; METHYLPHENIDATE; NEFAZODONE; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; NORTRIPTYLINE; PARACETAMOL; PAROXETINE; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RECOMBINANT ERYTHROPOIETIN; RIBAMIDINE; RIBAVIRIN; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; STEROID; UNCLASSIFIED DRUG; VENLAFAXINE; ALPHA2A INTERFERON; ALPHA2B INTERFERON; DRUG CARRIER; MACROGOL DERIVATIVE; PEGINTERFERON ALFA-2B;

ACUTE KIDNEY FAILURE; ACUTE PSYCHOSIS; ALOPECIA; AMNESIA; ANEMIA; ANOREXIA; ANXIETY DISORDER; ARTHRALGIA; BRONCHIOLITIS; CELIAC DISEASE; CONGESTIVE HEART FAILURE; CONSTIPATION; DEPRESSION; DERMATITIS; DISEASE EXACERBATION; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; FATIGUE; FEVER; GRAFT REJECTION; HEADACHE; HEART ARRHYTHMIA; HEMOLYSIS; HEPATITIS C; HUMAN; HYPERTENSION; HYPERTHYROIDISM; HYPOTHYROIDISM; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INJECTION SITE; INSOMNIA; INSULIN DEPENDENT DIABETES MELLITUS; INTERSTITIAL PNEUMONIA; IRRITABILITY; ISCHEMIC HEART DISEASE; MAJOR DEPRESSION; MANIA; MOOD DISORDER; MYALGIA; MYASTHENIA GRAVIS; NAUSEA; NEPHROLITHIASIS; NEPHROTIC SYNDROME; NEUTROPENIA; ORGANIZING PNEUMONIA; PATIENT MONITORING; PHOTODERMATOSIS; PRIORITY JOURNAL; PSORIASIS; RETINA HEMORRHAGE; RETINA VEIN OCCLUSION; REVIEW; RIGOR; SARCOIDOSIS; SEDATION; SEXUAL DYSFUNCTION; SKIN ULCER; STROKE; SUICIDE; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA; TINNITUS; TRANSIENT ISCHEMIC ATTACK; TREATMENT INDICATION; TREATMENT WITHDRAWAL; URINE RETENTION; VEIN THROMBOSIS; VISUAL IMPAIRMENT; WEIGHT GAIN; XEROSTOMIA; CHEMICALLY INDUCED DISORDER; DRUG COMBINATION; HEMATOLOGIC DISEASE;

ANTIVIRAL AGENTS; DEPRESSIVE DISORDER; DRUG CARRIERS; DRUG THERAPY, COMBINATION; HEMATOLOGIC DISEASES; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; POLYETHYLENE GLYCOLS; RIBAVIRIN;

EID: 16644379924     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2004.02192.x     Document Type: Review

References (55)

1. Strader DB, Wright T, Thomas DL, Seeff LB. AASLD practice guideline: diagnosis, management, and treatment of hepatitis C. Hepatology 2004; 39: 1147-71.
2. Manns MP, McHutchison JG, Gordon SC, et al. Peg-interferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358: 958-65.
3. Fried MW, Shiffman ML, Reddy KR, et al. Peg-interferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.
4. Hadziyannis SJ, Sette H, Morgan TR, et al. Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C. Ann Intern Med 2004; 140: 346-55.
5. McHutchison JG, Manns M, Patel K, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002; 123: 1061-9.
6. Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology 2002; 36: S237-44.
7. Zapater P, Lasso De La Vega MC, Horga JF, et al. Pharmacokinetic variations of acetaminophen according to liver dysfunction and portal hypertension status. Aliment Pharmacol Ther 2004; 20: 1-8.
8. Laffi G, LaVilla G, Pinzani M, Marra F, Gentilini P. Arachidonic acid derivatives and renal function in liver cirrhosis. Semin Nephrol 1997; 17: 530-48.
9. Hourigan LF, MacDonald GA, Purdie D, et al. Fibrosis in chronic hepatitis C, correlates significantly with body mass index and steatosis. Hepatology 1999; 29: 1215-9.
10. Adinoffi LE, Cambardella M, Adreana A, Tripodi MF, Utili R, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001; 33: 1358-64.
11. Poynard T, Ratziu V, McHutchison J, et al. Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology 2003; 38: 75-85.
12. Patton HM, Patel K, Behling C, et al. The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. J Hepatol 2004; 40: 484-90.
13. Lam NP, Pitrak D, Speralakis R, Lau AH, Wiley TE, Layden TJ. Effect of obesity on pharmacokinetics and biologic effect of interferon-alpha in hepatitis C. Dig Dis Sci 1997; 42: 178-85.
14. Cotler SJ, Wartelle CF, Larson AM, Gretch DR, Jensen DM, Carithers RL Jr. Pretreatment symptoms and dosing regimen predict side-effects of interferon therapy for hepatitis C. J Viral Hepat 2000; 7: 211-7.
15. Cotler SJ, Paul R, McNutt RA, et al. Patients' values for health states associated with hepatitis C and physicians' estimates of those values. Am J Gastroenterol 2001; 96: 2730-6.
16. Foster GR, Goldin RD, Thomas HC. Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology 1998; 27: 209-12.
17. Singh N, Gayowski T, Wagener MM, Marino IR. Vulnerability to psychological distress and depression in patients with endstage liver disease due to hepatitis C virus. Clin Transplant 1997; 11: 406-11.
18. Golding CO, Connell P, Murray FE. Prevalence of fibromyalgia, anxiety and depression in chronic hepatitis C virus infection: relationship to RT-PCR status and mode of acquisition. Eur J Gastroenterol Hepatol 2001; 13: 507-11.
19. Johnson ME, Fisher DG, Fenaughty A, Theno SA. Hepatitis C virus and depression in drug users. Am J Gastroenterol 1998; 93: 785-9.
20. Dieperink E, Willenbring M, Ho SB. Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: a review. Am J Psychiatry 2000; 157: 867-76.
21. Otsubo T, Miyaoka H, Kamijima K, et al. Depression during interferon therapy in chronic hepatitis - a prospective study. Seishin Shinkeigaku Zasshi 1997; 99: 101-27.
22. Pariante CM, Orru MG, Baita A, Farci MG, Carpiniello B. Treatment with interferon-alpha in patients with chronic hepatitis and mood or anxiety disorders. Lancet 1999; 354: 131-2.
23. Miyaoka H, Otsubo T, Kamijima K, Ishii M, Nuki M, Mitamura K. Depression from interferon therapy in patients with hepatitis C. Am J Psychiatry 1999; 156: 1120.
24. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis intervention Therapy Group. N Engl J Med 1998; 339: 1485-92.
25. Davis GL, Esteban-Muir R, Rustgi V, et al. Interferon alfa-2a alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 1998; 339: 1493-9.
26. Goldman LS. Successful treatment of interferon alfa-induced mood disorder with nortriptyline. Psychosomatics 1994; 35: 412-3.
27. Schramm TM, Lawford BR, Macdonald GA, Cooksley WG. Sertraline treatment of interferon-alfa-induced depressive disorder. Med J Aust 2000; 173: 359-61.
28. Levenson JL, Fallon HJ. Fluoxetine treatment of depression caused by interferon-alpha. Am J Gastroenterol 1993; 88: 760-1.
29. Gleason OC, Yates WR. Five cases of interferon-alpha-induced depression treated with antidepressant therapy. Psychosomatics 1999; 40: 510-2.
30. Maddock C, Baita A, Orru MG, et al. Psychopharmacological treatment of depression, anxiety, irritability and insomnia in patients receiving interferon-alpha: a prospective case series and a discussion of biological mechanisms. J Psychopharmacol 2004; 18: 41-6.
31. Musselman DL, Lawson DH, Gumnick JF, et al. Paroxetine for the prevention of depression induced by high-dose interferon alpha. N Engl J Med 2001; 344: 961-6.
32. Hauser P, Khosla J, Aurora H, et al. A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. Mol Psychiatry 2002; 7: 942-7.
33. Pockros PJ, Carithers R, Desmond P, et al. Efficacy and safety of a 2-dose regimens of peg interferon alfa-2a compared with interferon alfa-2a in chronic hepatitis C: a multicenter randomized controlled trial. Am J Gastroenterol 2004; 99: 1298-305.
34. Kontorinis N, Agarwal K, Dieterich DT. Current status of the use of growth factors and other adjuvant medications in patients receiving peginterferon and ribavirin. Rev Gastroenterol Disord 2004; 4(Suppl. 1): S39-47.
35. Soza A, Everhart JE, Glramy MG, et al. Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C. Hepatology 2002; 36: 1273-9.
36. Ahmed F, Jacobson IM, Brown RS Jr, et al. Clinical significance of pegylated interferon induced neutropenia: results from the WIN-R trial. Gastroenterology 2003; 124: A-700.
37. Peck-Radosavljevic M, Wichlas M, Pidlich J, et al. Blunted thrombopoietin response to interferon alfa-induced thrombocytopenia during treatment for hepatitis C. Hepatology 1998; 28: 1424-9.
38. Wang Q, Miyakawa Y, Fox N, Kaushansky K. Interferon-alpha directly represses megakaryopoiesis by inhibiting thrombopoietin-induced signaling through induction of SOCS-1. Blood 2000; 96: 2093-9.
39. Pockros PJ, Duchini A, McMillan R, Nyberg LM, McHutchison J, Viernes E. Immune thrombocytopenic purpura in patients with chronic hepatitis C virus infection. Am J Gastroenterol 2002; 97: 2040-5.
40. Marinos G, Rustgi VK. Safety of interferon/ribavirin therapy in patients with thrombocytopenia using recombinant human IL-11 (Abstract 639). Hepatology 2001; 34: 332A.
41. Lindahl K, Schvarcz R, Bruchfeld A, Stahle L. Evidence that plasma concentration rather than dose per kilogram body weight predicts ribavirin-induced anaemia. J Viral Hepat 2004; 11: 84-7.
42. De Franceschi L, Fattovich G, Turrini F, et al. Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage. Hepatology 2000; 31: 997-1004.
43. Peck-Radosavljevic M, Wichlas M, Homoncik-Kraml M, et al. Rapid suppression of hematopoiesis by standard or pegylated interferon-alpha. Gastroenterology 2002; 123: 141-51.
44. Tanaka N, Ishida F, Tanaka E. Ribavirin-induced pure red-cell aplasia during treatment of chronic hepatitis C. N Engl J Med 2004; 350: 1264-5.
45. PEG-Intron™ (recombinant peginterferon alfa-2b) package insert. Kenilworth, NJ: Schering Corporation, 2003.
46. Jen JF, Glue P, Gupta S, et al. Population pharmacokinetic and pharmacodynamic analysis of ribavirin in patients with chronic hepatitis C. Ther Drug Monit 2000; 22: 555-65.
47. Shiffman ML, Di Bisceglie AM, Lindsay KL, et al. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 2004; 126; 1015-23.
48. Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virologic response to treatment with peg interferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003; 38: 645-52.
49. Afdhal NH, Dieterich DT, Pockros PJ, et al. Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. Gastroenterology 2004; 126: 1302-11.
50. Azzam H, Ahmed F, Peterson B, et al. Delayed recovery of pegylated interferon and ribavirin induced anemia. Hepatology 2003; 38: 751A (abstract).
51. Younossi ZM, Ong JP, Collantes R, et al. Darbepoetin alfa for ribavirin-induced anemia in patients with chronic hepatitis C treated with pegylated interferon and ribavirin: a preliminary analysis. Gastroenterology 2004; 126: A666 (abstract).
52. Lau JY, Tam RC, Liang TJ, Hong Z. Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. Hepatology 2002; 35: 1002-9.
53. Watson J. Prospects for hepatitis C virus therapeutics: levovirin and viramidine as improved derivatives of ribavirin. Curr Opin Investig Drugs 2002; 3: 680-3.
54. Wu JZ, Walker H, Lau JY, Hong Z. Activation and deactivation of a broad-spectrum antiviral drug by a single enzyme: adenosine deaminase catalyzes two consecutive deamination reactions. Antimicrob Agents Chemother 2003; 47: 426-31.
55. Gish R, Arora S, Nelson D, et al. Safety and Efficacy of Viramidine in Combination with Pegylated Interferon Alfa-2a for Treatment of Hepatitis C in Therapy-naive Patients. Program and Abstracts of the 39th Annual Meeting of The European Association for the Study of the Liver Berlin, Germany, 2004 (abstract 479/762).